Project information
From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
- Project Identification
- MSM0021622434
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Keywords
- multiple myeloma; proteomics; genomics
Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.
Publications
Total number of publications: 313
2012
-
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma
Leukemia & Lymphoma, year: 2012, volume: 53, edition: 7, DOI
-
Kladribin je velmi účinným lékem pro léčbu histiocytózy z Langerhansových buněk a vzácných histiocytárních nemocí ze skupiny juvenilního xantogranulomu
Vnitřní lékařství, year: 2012, volume: 58, edition: 6
-
Kožní a mimokožní projevy histiocytózy z Langerhansových buněk v obrazech
Česká dermatovenerologie, year: 2012, volume: 2, edition: 1
-
Léčba histiocytózy z Langerhansových buněk kladribinem dosáhla u 9 z 10 dospělých pacientů dlouhodobé kompletní remise
Klinická onkologie, year: 2012, volume: 25, edition: 4
-
Lenalidomid indukoval léčebnou odpověď u pacienta s agresivní multisystémovou formou histiocytózy z Langerhansových buněk (LCH), rezistentní ke 2-chlorodeoxyadenosinu a časně relabující po vysokodávkované chemoterapii ...
Vnitřní lékařství, year: 2012, volume: 58, edition: 1
-
Lenalidomide proved effective in multisystem Langerhans cell histiocytosis
Acta Oncologica, year: 2012, volume: 51, edition: 3, DOI
-
Lenalidomide: a new treatment option for Castleman disease
Leukemia & Lymphoma, year: 2012, volume: 53, edition: 10, DOI
-
Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma
Nuclear Medicine and Biology, year: 2012, volume: 39, edition: 3, DOI
-
Mechanism of immunomodulatory drugs in multiple myeloma
Leukemia Research, year: 2012, volume: 36, edition: 10, DOI
-
MikroRNA v onkologii
Year: 2012, edition: 1.vyd., number of pages: 324 s.